| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Dendreon Taps Financing Sooner Than Expected
Posted on 06/05/2007 06:20:30 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Shares of Dendreon (DNDN) are trading down some 7% pre-market after the company announced that it was going to offer $75 million in convertible senior subordinated notes that are due in 2014. The offering is being made under Rule 144A to qualified institutional buyers, so the securities will not be required to be registered until a reseale period.
The terms are still T.B.A. and are being negotiated, plus their is a $25 million overallotment option.
The Company intends to use the net proceeds of this offering to finance its activities relating to the potential commercialization of Provenge®, expand its manufacturing facilities for the commercial production of PROVENGE...
Continue article at 247WallSt.com
RELATED READING:
- Analysts Continue to Dump on Dendreon
- Dendreon Catches a Break From The FDA
- Dendreon Volume and Volatility Compress Ahead of ASCO
_____________________
24/7 Wall St.
Shares of Dendreon (DNDN) are trading down some 7% pre-market after the company announced that it was going to offer $75 million in convertible senior subordinated notes that are due in 2014. The offering is being made under Rule 144A to qualified institutional buyers, so the securities will not be required to be registered until a reseale period. The terms are still T.B.A. and are being negotiated, plus their is a $25 million overallotment option.
The Company intends to use the net proceeds of this offering to finance its activities relating to the potential commercialization of Provenge®, expand its manufacturing facilities for the commercial production of PROVENGE...
Continue article at 247WallSt.com
RELATED READING:
- Analysts Continue to Dump on Dendreon
- Dendreon Catches a Break From The FDA
- Dendreon Volume and Volatility Compress Ahead of ASCO
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- e-techblog
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Millionaire Now! by Larry Nusbaum
- 360 Digest
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]
I used to make a pretty good living sharing hard won [read more]
<< My Home | TheMoneyBlogs Home